AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-17. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The racial makeup of Raleigh in 2023 was 52.5% non-Hispanic White, 28.1% Black or African American, 0.3% American Indian or Alaska Native, 4.5% Asian American, 0.1% from some other race, 6.9% two or more races, 11.6% Hispanic or Latin American of any race. According to the 2010 United States census, the racial composition of the city was: 57.5% White (53.3% non-Hispanic White), 29.3% Black or African American, 4.3% Asian American (1.2% Indian, 0.8% Chinese, 0.7% Vietnamese, 0.5% Korean, 0.4% Filipino, 0.1% Japanese), 2.6% two or more races, 1.4% some other race, 0.5% Native American, and <0.1% Native Hawaiian or other Pacific Islander In addition, 11.4% of city residents were Hispanic or Latino Americans, of any race (5.9% Mexican, 1.1% Puerto Rican, 0.9% Salvadoran, 0.6% Dominican, 0.6% Honduran, 0.3% Colombian, 0.3% Cuban, 0.2% Guatemalan, 0.2% Spanish, 0.2% Peruvian, 0.1% Venezuelan, 0.1% Ecuadorian, 0.1% Argentine, and 0.1% Panamanian). In 2000, the racial composition of the city was: 63.31% White, 27.80% Black or African American, 7.01% Hispanic or Latino American, 3.38% Asian American, 0.36% Native American, 0.04% Native Hawaiian or other Pacific Islander, 3.24% some other race, and 1.88% two or more races.
=== Middle Eastern culture === The scorpion is a culturally significant animal, appearing as a motif in art, especially in Islamic art in the Middle East. A scorpion motif is often woven into Turkish kilim flat-weave carpets, for protection from their sting. The scorpion is perceived both as an embodiment of evil and a protective force such as a dervish's powers to combat evil. In another context, the scorpion portrays human sexuality. Scorpions are used in folk medicine in South Asia, especially in antidotes for scorpion stings. One of the earliest occurrences of the scorpion in culture is its inclusion, as Scorpio, in the 12 signs of the Zodiac by Babylonian astronomers during the Chaldean period. In ancient Egypt, the goddess Serket was often depicted as a scorpion, one of several goddesses who protected the Pharaoh. Alongside serpents, scorpions are used to symbolize evil in the New Testament. In Luke 10:19 it is written, "Behold, I give unto you power to tread on serpents and scorpions, and over all the power of the enemy: and nothing shall by any means hurt you." Here, scorpions and serpents symbolize evil. Revelation 9:3 speaks of "the power of the scorpions of the earth."
== Electromyography == Electromyography is a research technique that allows researchers to look at muscle recruitment in various conditions, by quantifying electrical signals sent to muscle fibers through motor neurons. In general, fatigue protocols have shown increases in EMG data over the course of a fatiguing protocol, but reduced recruitment of muscle fibers in tests of power in fatigued individuals. In most studies, this increase in recruitment during exercise correlated with a decrease in performance (as would be expected in a fatiguing individual). Median power frequency is often used as a way to track fatigue using EMG. Using the median power frequency, raw EMG data is filtered to reduce noise and then relevant time windows are Fourier Transformed. In the case of fatigue in a 30-second isometric contraction, the first window may be the first second, the second window might be at second 15, and the third window could be the last second of contraction (at second 30). Each window of data is analyzed and the median power frequency is found. Generally, the median power frequency decreases over time, demonstrating fatigue. Some reasons why fatigue is found are due to action potentials of motor units having a similar pattern of repolarization, fast motor units activating and then quickly deactivating while slower motor units remain, and conduction velocities of the nervous system decreasing over time.
Sources: en.wikipedia.org
In these enzymes, both substrates bind to the enzyme at the same time to produce an EAB ternary complex. The order of binding can either be random (in a random mechanism) or substrates have to bind in a particular sequence (in an ordered mechanism). When a set of v by [S] curves (fixed A, varying B) from an enzyme with a ternary-complex mechanism are plotted in a Lineweaver–Burk plot, the set of lines produced will intersect. Enzymes with ternary-complex mechanisms include glutathione S-transferase, dihydrofolate reductase and DNA polymerase. Substituted-enzyme ("ping–pong") mechanisms
=== Initial effects on wartime assistance === It also led to a pause in other efforts such as wartime help in Ukraine, hospital assistance in Syria, education programs in Mali, and conservation efforts in the Amazon rainforest. On February 6, CBS News reported that due to the civil war in Sudan, often called the “Forgotten War” because it receives comparatively little attention compared to the Ukraine and Gaza, an estimated 3 million children under age 5 are suffering from acute malnutrition. The American Farm Bureau Federation stated, "AID plays a critical role in reducing hunger around the world while sourcing markets for the surplus foods America's farmers and ranchers grow".
==== Distribution ==== The apparent volume of distribution of gepirone is approximately 94.5 L. The plasma protein binding of gepirone in vitro is 72% and is independent of concentration. The plasma protein binding of 3'-OH-gepirone is 59% and of 1-PP is 42%.
== Structure == Convulxin is a heterodimer made up of α-(13.9 kDa) and β- (12.6 kDa) subunits, with 38% sequence identity and homologous structures. The subunits are connected by disulfide bridges to form a cyclic, ring-like α4β4 structure . Its function arises from its ability to bind with high affinity to the platelet receptor for collagen, glycoprotein (GP) VI. It is, therefore, an important task to determine the binding site on the heterodimer to the GPVI. The heterodimer structure presents a concave surface, predicted to be the ligand binding site. Furthermore, general research into the C-type lectin family describes the binding site as being formed by loop regions, falling between the second α-helix and the second β-strand on both the α- and β-subunits. Investigating the particular sequences of these structures showed high variability, suggesting that it is indeed these variable, concave loops that offer specificity in ligand binding. Analysis on the specific Cvx structure has revealed 3 possible sites of interaction with GPVI. Firstly, two adjacent patches of positive and negative charge on the α-subunit; secondly, a cavity in the same subunit lines with the following residues:Trp23, Ser67, Leu104, Ala117, Gly121 and Ile123; finally, a negatively charged patch on the β-subunit.
Sources: en.wikipedia.org
==== Shortage of 237Np stockpiles ==== The long half-life (88 years) of 238Pu and the absence of γ-radiation that could interfere with the operation of on-board electronic components, or irradiate people, makes it the radionuclide of choice for electric thermogenerators. 237Np is therefore a key radionuclide for the production of 238Pu, which is essential for deep space probes requiring a reliable and long-lasting source of energy without maintenance. Stockpiles of 238Pu built up in the United States since the Manhattan Project, thanks to the Hanford nuclear complex (operating in Washington State from 1943 to 1977) and the Savannah River Site (operating in South Carolina from 1950 to 1988) the development of atomic weapons, are now almost exhausted. The extraction and purification of sufficient new quantities of 237Np from irradiated nuclear fuels is therefore necessary for the resumption of 238Pu production in order to replenish the stocks needed for space exploration by robotic probes.
== PCSK subtypes == To date there are 9 PCSKs with varying functions and tissue distributions. Often, due to similar times of discovery from different groups the same PCSKs have acquired multiple names. In an attempt to alleviate confusion, there is a trend towards using the PCSK prefix with the appropriate number suffix.
=== Beta-blockers === Many of the common symptoms of hyperthyroidism, such as palpitations, trembling, and anxiety, are mediated by increases in beta-adrenergic receptors on cell surfaces. Beta blockers, typically used to treat high blood pressure, are a class of drugs that offset this effect, reducing the rapid pulse associated with palpitations, and decreasing tremor and anxiety. Thus, a person with hyperthyroidism can often obtain immediate temporary relief until the hyperthyroidism can be characterized with the Radioiodine test noted above, and more permanent treatment takes place. Note that these drugs do not treat hyperthyroidism or any of its long-term effects if left untreated, but rather, they treat or reduce only symptoms of the condition. Some minimal effect on thyroid hormone production also comes with propranolol, which has two roles in the treatment of hyperthyroidism, determined by the different isomers of propranolol. L-propranolol causes beta-blockade, thus treating the symptoms associated with hyperthyroidism, such as tremor, palpitations, anxiety, and heat intolerance. D-propranolol inhibits thyroxine deiodinase, thereby blocking the conversion of T4 to T3, providing some, though minimal, therapeutic effect. Other beta-blockers are used to treat only the symptoms associated with hyperthyroidism. Propranolol in the UK, and metoprolol in the US, are most frequently used to augment treatment for people with hyperthyroidism.
NADH:ubiquinone reductase (non-electrogenic) (EC 1.6.5.9, NDH-2, ubiquinone reductase, coenzyme Q reductase, dihydronicotinamide adenine dinucleotide-coenzyme Q reductase, DPNH-coenzyme Q reductase, DPNH-ubiquinone reductase, NADH-coenzyme Q oxidoreductase, NADH-coenzyme Q reductase, NADH-CoQ oxidoreductase, NADH-CoQ reductase) is an enzyme with systematic name NADH:ubiquinone oxidoreductase. This enzyme catalyses the following chemical reaction:
Dorothy Anderson, Administrative Officer, Department of Social Security. John Elwyn Anderson. For services to the community, particularly Lifesaving, in South Wales. Royan Stuart Anderson, Constable, Operational Support Unit, British Transport Police. For services to Public Transport. Timothy John Anderson, Sergeant, Derbyshire Constabulary. For services to the Police. Edmund Robert Askey. For services to Tourism in Blackpool, Lancashire. Charles Keith Atkinson. For services to Young People in Nottinghamshire and to Rowing. Elizabeth Atkinson, Member, Northumberland County Council. For services to Local Government. Marjone Oxnard Atkinson. For services to the community on the Pennywell Estate, Sunderland, Tyne and Wear. Peggy Baerlein. For services to the Lister Hospital, Hertfordshire. Beryl Bailey, Support Grade Band 1, Home Office. Peter Edwin Bailey, lately Senior Doorkeeper, House of Lords. Albert John Baker. For services to War Pensions Committees in London. Elsie Evelyn Baker. For services to the Girls' Brigade on Guernsey. Kenneth Walter Ball, lately Honorary Secretary, British Transport Pensioners' Federation. For services to the Railway Industry. Jack Bonner Barlow. For services to Local Councils in the former South Glamorgan and to the community in Sully. Andrew Brown Barr. For services to the Royal Agricultural Benevolent Institution and to the Essex Agricultural Society. Dennis Gordon Bartholomew. For services to the community in Whiston, South Yorkshire. Haydn Sydney Bateman, Auxiliary Coastguard-in-charge, Her Majesty's Coastguard, St Govans, Dyfed.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.